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Abstract
Background—An rs3890011 variant of CYP4A11, which is in linkage disequilibrium with the
loss-of-function variant rs1126742, is associated with hypertension in humans. In mice, Cyp4a
deficiency results in salt-sensitive hypertension through activation of ENaC. We tested the
hypothesis that the rs3890011 variant is associated with blood pressure response to drugs acting
via the ENaC pathway.
Methods and Results—African Americans with volume-dependent, resistant hypertension
were randomized to treatment with placebo, spironolactone, amiloride, or combination. Blood
pressure responses were analyzed by CYP4A11 genotypes. Rs3890011 (GG:GC:CC=20:35:28)
and rs1126742 (TT:TC:CC=45:31:7) were in linkage disequilibrium (D′=1, r=0.561). Expected
small number of rs1126742 CC homozygotes precluded analysis of the effect of this genotype on
treatment responses. Spironolactone reduced blood pressure in rs3890011 GG and GC individuals,
but not in CC homozygotes (p=0.002), whereas amiloride reduced blood pressure similarly in all
rs3890011 genotypes. The antihypertensive effects of spironolactone and amiloride were
comparable in GG and GC participants, but only amiloride reduced pressure in CC homozygotes
(−6.3±7.3/−3.2±4.0 versus +6.8±7.9/+4.8±8.6 mmHg, p<0.01/<0.05). The aldosterone response to
spironolactone was also blunted in the CC genotype.
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Conclusions—In individuals homozygous for the CYP4A11 rs3890011 C allele, blood pressure
is resistant to mineralocorticoid receptor antagonism, but sensitive to ENaC inhibition, consistent
with ENaC activation. Studies in a larger population are needed to replicate these findings.
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Introduction
The cytochrome P450 ω-hydroxylase CYP4A11 oxidizes arachidonic acid to 20-
hydroxyeicosatetraenoic acid (20-HETE), which causes both vasoconstriction and
natriuresis. (1) In humans, a variant in intron 10 of CYP4A11 (rs3890011) with a relatively
high minor allele frequency was associated with systolic blood pressure (SBP) in
normotensive Chinese men (p=0.05 after controlling for age and body mass index), and a
haplotype containing the C allele of rs3890011 was associated with hypertension in women.
(2) A nearby loss-of-function variant in exon 11 of CYP4A11 (rs1126742, T8590C, or
Phe434Ser), in linkage disequilibrium with rs3890011 but with a much lower minor allele
frequency (17.4%), has been associated with hypertension in several populations. (3–6) In
addition, this polymorphism has been associated with the sensitivity of blood pressure to salt
intake in hypertensive individuals. (7)
In mice, genetic deficiency of the ω-hydroxylase Cyp4a10 results in salt-sensitive
hypertension but does not cause a change 20-HETE synthase activity. Hypertension results
from increased sodium reabsorption due to constitutive activation of the epithelial sodium
channel (ENaC) mediated by a decrease in epoxygenase activity and renal synthesis of
epoxyeicosatrienoic acids (EETs). (8) Treatment of Cyp4a10−/− mice with the ENaC
antagonist amiloride normalizes blood pressure. This is analogous to the situation in Liddle
syndrome, a Mendelian form of human hypertension in which mutations in either the β or γ
subunit of ENaC result in gain-of-function and sodium retention that can be corrected by
treatment with amiloride but not with spironolactone. (9,10)
The CYP4A11 variant rs1126742 encodes for an enzyme with reduced catalytic activity, (6)
making it conceivable that the associated salt-sensitive hypertension is due to deficient 20-
HETE synthesis. In contrast, the mechanism for the association between the intronic variant
rs3890011 and increased blood pressure is not known. We hypothesized that it may be
associated with increased ENaC activity. If this were the case, the hypertension would be
resistant to treatment with the mineralocorticoid receptor (MR) antagonist spironolactone
but sensitive to the ENaC inhibitor amiloride. To test this hypothesis, we compared the
blood pressure response to placebo, spironolactone, amiloride, and the combination of
spironolactone and amiloride in an exploratory pilot study in 83 hypertensive African
Americans who participated in a published randomized clinical trial, (11) and for whom
DNA was available, according to the CYP4A11 genotype at rs3890011.
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Methods
The study protocol was approved by the Indiana University-Purdue University at
Indianapolis institutional review board. All patients gave written informed consent.
Patients were eligible for enrollment if they were self-identified as black (defined as of
African descent), between 18 and 75 years of age, and had a SBP >140 and ≤175 mm Hg or
a diastolic blood pressure (DBP) >90 and ≤105 mm Hg while receiving any of the following
- hydrochlorothiazide (minimum dose of 25 mg), furosemide (minimum dose of 40 mg),
equivalent doses of similar diuretics and amlodipine 5 or 10 mg, or equivalent doses of a
similar calcium channel blocker. (11) Any use of triamterene, an angiotensin-converting
enzyme (ACE) inhibitor, or an angiotensin receptor blocker was discontinued for 1 month
before the study. To restrict enrollment to patients with hypertension that was more volume
dependent, patients were excluded if their plasma renin activity (PRA) exceeded 2.0 ng/mL
per hour.
Protocol
Patients completed a randomized, placebo-controlled, double-blind, parallel-group trial that
used a 2-by-2 factorial design, as previously described. (11) They were screened at least 3
weeks prior to randomization and eligible subjects were given 2 placebo capsules to take
each morning for 3 weeks. They were then randomized to one of four treatment groups:
amiloride (10 mg per day), spironolactone (25 mg per day), the combination of both drugs,
and placebo. Study medications were given as two identical appearing capsules. Blood
pressure measurements and blood samples were obtained at baseline and at weeks 1, 3, 5, 7,
and 9. Blood pressure was measured three times in the morning prior to study medication
while patients were seated; the average of the last two readings was used in the analyses.
Laboratory Analysis
Serum electrolytes and creatinine were measured using a Vitros 950 instrument (Ortho
Clinical Diagnostics). PRA was measured using a radioimmunoassay for angiotensin I
(Clinical Assays GammaCoat kit); the intra-assay coefficient of variation (CV) was 4.6%,
and the interassay CV was 7.6%. (11) Aldosterone was also measured by radioimmunoassay
(Diagnostic Products Corporation), and the intra-assay and interassay CVs were 5.4% and
13.1%, respectively.
Genetic Analysis
Genotyping for SNP rs3890011 of CYP4A11 was performed by amplification and
sequencing of a DNA segment covering exon 10 through exon 11, as previously described.
(3) Genotyping for rs1126742 was also obtained to verify allele frequencies in our
population.
Statistical Analysis
Data are presented as mean ± standard deviation unless otherwise indicated. Primary end
points were the changes from baseline in SBP and DBP at nine weeks of therapy. Secondary
end points were changes in PRA and plasma aldosterone and in serum levels of potassium
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and creatinine. Change from baseline to 9 weeks was calculated for each study participant.
Deviation from Hardy-Weinberg was calculated using chi square testing. The effect of
genotype on response to treatment was tested using ANCOVA, in which the age at onset of
hypertension, sex, and baseline were included as covariates. Change in potassium was also
included as a covariate in an ANOVA assessing the effect of rs3890011 genotype on
aldosterone concentrations. Plasma aldosterone concentrations and PRA were transformed
using the natural log prior to analysis. A p value less than 0.05 was considered significant.
Results
The frequencies of both rs3890011 and rs1126742 were in Hardy-Weinberg equilibrium and
their genotypes were in linkage disequilibrium (D′=1, r=0.561, p<0.001). The frequency of
the minor allele for the loss-of-function variant at rs1126742 was 27.1%, similar to the
previously reported 30.0% for African Americans, (3) confirming our prediction that
genotypic analyses of therapeutic responses would not be possible in a population the size of
ours, owing to the low number of CC homozygous subjects (TT:TC:CC=45:31:7). The only
significant difference related to rs1126742 genotype was detected in all patients combined
(four therapy groups). We observed a failure of aldosterone levels to increase in response to
treatment in CC subjects (Figure 1), compared to TT and CT, who exhibited the expected
increase in this hormone in response to MR or ENaC blockade. (12,13)
In contrast, the frequency of the minor allele for rs3890011 was 54.8%, higher in this group
of African American subjects than that reported in Chinese (2) and in the 1000 Genomes
database (41.5%), (14) with a genotype distribution allowing for the testing of our
hypothesis (GG:GC:CC=20:35:28).
Table 1 provides baseline characteristics for subjects according to rs3890011 genotype.
There was no difference in blood pressure, the number of anti-hypertensive medications, or
any other baseline variable among genotypes. There was also no difference in the classes of
anti-hypertensive medications used among genotype groups randomized to spironolactone or
not.
Figure 2 shows that placebo-induced changes in blood pressure over the period of study
were not different among the three rs3890011 genotypes (panel A). There was no reduction
in SBP and DBP in response to spironolactone monotherapy in the 5 CC homozygous
subjects, significantly different from the reductions observed in the 7 GG and 8 GC (panel
B). In contrast, amiloride monotherapy reduced SBP and DBP similarly in all CYP4A11
rs3890011 genotypes (GG:GC:CC=6:8:6, panel C). In a sensitivity analysis, there was a
significant association between CYP4A11 rs3890011 genotype (GG:GC:CC=12:15:13) and
blood pressure response to any spironolactone-containing treatment (Figure 3) but not to any
amiloride-containing therapy (p>0.15, not shown). Finally, in all subjects carrying at least
one rs3890011 G allele (GG+GC) amiloride reduced SBP and DBP (−10.6±8.2/−5.9±6.4
mmHg) to the same extent as spironolactone (−9.8±9.4/−6.3±6.5 mmHg), p=0.41/0.43. In
contrast, in CC homozygous subjects amiloride reduced SBP and DBP (−6.3±7.3/−3.2±4.0
mmHg) to a greater extent than spironolactone did (+6.8±7.9/+4.8±8.6), p<0.01/<0.05. The
increase in SBP of CC with spironolactone monotherapy was significant (p<0.03) but not
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significantly different from that sustained by all subjects given placebo during the trial
(3.6±11.3), p=0.28. There was no effect of gender or BMI on response to spironolactone or
amiloride, alone or in combination.
Aldosterone responses to therapy followed a similar pattern. In subjects carrying at least one
G allele (GG+GC), amiloride increased aldosterone from 452±58 to 784±97 pmol/L and
spironolactone increased aldosterone from 352±53 to 596±91 pmol/L (drug comparison not
significant, adjusted marginal means after controlling for gender and change in potassium).
In contrast, in CC homozygous subjects, amiloride increased aldosterone from 585±89 to
989±144 pmol/L, whereas spironolactone did not affect aldosterone (from 446±91 to
449±147 pmol/L, p=0.038 for drug comparison). There were no other significant
relationships between CYP4A11 rs3890011 and the effect of either spironolactone or
amiloride on heart rate, PRA, plasma sodium, plasma potassium, or creatinine.
Discussion
Gain-of-function mutations in ENaC such as occur in Liddle syndrome result in salt-
sensitive hypertension that is resistant to MR antagonists but responds to the ENaC inhibitor
amiloride. (9,10) In rodent models, decreased expression of Cyp4a also results in increased
ENaC activity and salt-sensitive hypertension that is responsive to amiloride. (8,15) We
report for the first time in this exploratory pilot study that African Americans with resistant,
volume-dependent hypertension who are homozygous for the C allele at rs3890011 of
CYP4A11, an allele previously associated with blood pressure (2), are resistant to the blood
pressure lowering effects of spironolactone but respond to amiloride.
Several lines of evidence in rodents suggest that CYP4A modulates ENaC function. First,
Nakagawa et al reported that genetic deficiency of CYP4a10 results in constitutive activity
of ENaC and salt-sensitive hypertension that is responsive to amiloride. (8) This is thought
to result from decreased formation of EETs that act as endogenous inhibitors of ENaC. In
the Dahl salt-sensitive rat, CYP4A genotype segregates with salt-sensitive hypertension. (16)
Decreased CYP4A hydroxylase activity results in salt-sensitive hypertension in this model,
whereas induction of CYP4A increases pressure natriuresis. More recently, Kakizoe et al
have reported that β and γ ENaC subunit mRNA and protein are overexpressed in Dahl salt-
sensitive rats. (15) They further reported that 4-week treatment with amiloride reduced
blood pressure and renal injury whereas treatment with eplerenone did not.
A common intronic variant of CYP4A11, rs3890011, is associated with blood pressure in the
Chinese. (2) We studied the association between this variant and the blood pressure
responses to amiloride and spironolactone in our population. The rs3890011 locus is 247
base pairs away and in linkage disequilibrium with rs1126742, a rarer coding variant of
CYP4A11. The latter variant in exon 11 encodes for a thymidine-to-cytosine substitution at
base pair 8590 that results in a Phe-to-Ser substitution at amino acid 434 and loss of function
of the product enzyme. (3) The low frequency of the minor allele of rs1126742 precludes
genotypic analyses in populations the size of ours, owing to the small number of
homozygous CC subjects. Therefore, we did not study the relationship between this
genotype and blood pressure responses to therapy in our small clinical trial. We were only
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able to document that the aldosterone response to treatment was diminished in rs1126742
CC homozygous subjects.
Whether there is a functional consequence of the rs3890011 intronic variant is not currently
known but the much larger frequency of its minor allele allowed us to examine the
relationship between this CYP4A11 polymorphism and the blood pressure response to
spironolactone and amiloride in African Americans with resistant hypertension and
suppressed PRA. The prevalence of salt-sensitive or volume-dependent hypertension is
increased among African Americans. (17) Genetic variants in ENaC that have been
associated with an increased urinary aldosterone/potassium ratio, an index of ENaC activity,
are more common in African Americans but have not been universally associated with
hypertension. (18,19) As previously published in this study population of African Americans
with volume-dependent resistant hypertension, amiloride alone has a greater effect on blood
pressure than does spironolactone alone. (11) Whereas it is possible that this relates to the
doses of spironolactone and amiloride used, our data suggest that this is also attributable to a
diminished response to spironolactone in subjects homozygous for the CYP4A11 rs3890011
C allele.
The loss-of-function CYP4A11 rs1126742 C allele is more common in African Americans
than in other ancestral groups (3) and we found the CYP4A11 rs3890011 C allele to be more
common in our African American study population than previously reported in Chinese. (2)
Whether the findings of this study will hold up in individuals with resistant hypertension
from other racial groups remains to be studied.
A limitation of our study is the small number of subjects, although the sensitivity analysis in
which we combined subjects in spironolactone treatment groups (Figure 3) supports the
conclusions. Also, baseline PRA and aldosterone concentrations were not significantly
lower in rs3890011 CC homozygotes, as one would expect if ENaC activity were increased.
The exclusion of subjects with a PRA greater than 2.0 ng/mL per hour and the use of
concomitant medications that affect PRA (e.g., diuretics and β-blockers) may have
confounded any relationship between CYP4A11 genotype and baseline PRA. Williams et al
previously reported the relationship between the CYP4A11 rs1126742 genotype and salt-
sensitivity of blood pressure in untreated subjects. (7) In that study, although there was no
significant relationship between genotype and PRA or aldosterone overall, there was a
significant relationship between CYP4A11 genotype and aldosterone in African Americans
during low salt (16.5±9.5, 14.9±7.2, and 7.9±3.4 ng/dL, in 36 TT, 33 CT, 5 CC,
respectively, p=0.03, unpublished). There was no relationship between CYP4A11 genotype
and PRA in African Americans in that study (unpublished).
In summary, inappropriate activation of ENaC has increasingly been recognized as a feature
of resistant hypertension. (20) The MR antagonists spironolactone and eplerenone are often
effective in reducing blood pressure in patients with resistant hypertension. (21,22) Not all
patients respond to MR antagonism, however, and in these patients amiloride may be more
effective. (11) Genetic variants in CYP4A11 have been associated with hypertension and
with salt-sensitive hypertension in particular. (2–7) The present data suggest that genetic
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variation in CYP4A11 might be used to predict individuals who should be treated with a
direct ENaC inhibitor. Additional studies are needed to replicate these findings.
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Figure 1.
Relationship between CYP4A11 rs1126742 (T8590C) genotype and aldosterone response to
any therapy including placebo, spironolactone, amiloride or combination amiloride and
spironolactone. Data are presented as means ± standard error.
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Figure 2.
Relationship between CYP4A11 rs3890011 genotype and blood pressure response after nine
weeks of treatment with (A) placebo, (B) spironolactone, (C) amiloride or (D) combination
amiloride and spironolactone. Data are presented as means ± standard error.
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Figure 3.
Relationship between CYP4A11 rs3890011 genotype and blood pressure response to
spironolactone in the presence or absence of amiloride (any spironolactone). Data are
presented as means ± standard error.
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Table 1
Baseline subject characteristics by CYP4A11 rs3890011 genotype
CYP4A11 rs3890011 Genotype GG (N=20) GC (N=35) CC (N=28)
Gender, M:F 12:8 16:19 16:12
Age, years 49.0±9.0 44.5±9.9 47.9±8.7
Body Mass Index, kg/M2 32.8±4.9 34.3±7.4 35.4±10.0
Duration of Hypertension, years 13.2±8.2 8.8±7.9 12.2±8.1
Number of Anti-Hypertensives 2.35±0.67 2.29±0.46 2.21±0.50
Class of Anti-Hypertensives, N (%)
 Thiazide diuretic 19 (95.0%) 31 (88.6%) 25 (89.3%)
 Loop diuretic 1 (5.0%) 4 (11.4%) 3 (10.7%)
 Amlodipine or other dihydropyridine 19 (95.0%) 33 (94.3%) 28 (100.0%)
 CCB other 1 (5.0%) 1 (2.9%) 0
 β-blocker 6 (30.0%) 10 (28.6%) 6 (21.4%)
 Alpha-2 agonist 2 (10%) 0 0
 Minoxidil 0 0 1 (3.8%)
 Alpha-1 antagonist 0 1 (2.8%) 1 (3.8%)
Systolic Blood Pressure (mmHg) 145.8±12.1 139.9±10.5 140.9±12.8
Diastolic Blood Pressure (mmHg) 91.5±7.8 92.1±6.0 89.4±8.9
Heart Rate (bpm) 79.4±9.2 75.5±10.3 78.5±8.8
Glucose (mg/dL) 123.6±39.0 105.7±30.8 117.4±46.4
Serum sodium (mmol/L) 141.8±2.0 142.1±1.9 141.6±2.4
Serum potassium (mmol/L) 3.6±0.4 3.6±0.4 3.7±0.3
Serum creatinine (mmol/L) 90.2±15.0 91.9±18.6 92.8±24.8
Plasma Renin Activity (ng/mL/min) 0.89±1.90 0.77±1.87 0.64±0.96
Aldosterone (pmol/L) 401.7±232.7 407.2±193.9 423.8±205.0
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